Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$183.36 +1.0%	$190.70	$137.23 ▼ $212.71	$284.38B	0.25	2.57 million shs	1.96 million shs
GSK GSK	$51.16 +1.0%	$53.38	$35.45 ▼ $61.69	$103.81B	0.36	4.85 million shs	6.11 million shs
NVO Novo Nordisk A/S	$42.21 +2.9%	$41.71	$35.12 ▼ $81.44	$188.49B	0.78	20.48 million shs	14.70 million shs
NVS Novartis	$149.18 +1.9%	$149.51	$112.34 ▼ $170.46	$284.66B	0.46	1.98 million shs	2.42 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	-2.29%	+1.06%	-0.49%	-6.76%	+24.73%
GSK GSK	-1.72%	+2.93%	+0.59%	-8.37%	+22.95%
NVO Novo Nordisk A/S	-4.36%	-6.73%	-10.79%	+6.00%	-45.04%
NVS Novartis	-1.60%	+0.70%	+0.46%	-9.27%	+24.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$183.36 +1.0%	$190.70	$137.23 ▼ $212.71	$284.38B	0.25	2.57 million shs	1.96 million shs
GSK GSK	$51.16 +1.0%	$53.38	$35.45 ▼ $61.69	$103.81B	0.36	4.85 million shs	6.11 million shs
NVO Novo Nordisk A/S	$42.21 +2.9%	$41.71	$35.12 ▼ $81.44	$188.49B	0.78	20.48 million shs	14.70 million shs
NVS Novartis	$149.18 +1.9%	$149.51	$112.34 ▼ $170.46	$284.66B	0.46	1.98 million shs	2.42 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	-2.29%	+1.06%	-0.49%	-6.76%	+24.73%
GSK GSK	-1.72%	+2.93%	+0.59%	-8.37%	+22.95%
NVO Novo Nordisk A/S	-4.36%	-6.73%	-10.79%	+6.00%	-45.04%
NVS Novartis	-1.60%	+0.70%	+0.46%	-9.27%	+24.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.85	Moderate Buy	$205.33	11.85% Upside
GSK GSK	1.89	Reduce	$53.00	3.26% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	56.53% Upside
NVS Novartis	2.31	Hold	$141.20	-5.50% Downside

Current Analyst Ratings Breakdown

Latest GSK, NVS, AZN, and NVO Analyst Ratings

Date	Company	Brokerage	Action	Rating
6/9/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/9/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
6/9/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/1/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/1/2026	AZN Astrazeneca	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/21/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
5/14/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/13/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/12/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
5/4/2026	AZN Astrazeneca	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/1/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B)

(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$60.44B	4.71	$12.77 per share	14.38	$31.41 per share	5.84
GSK GSK	$43.07B	2.42	$5.98 per share	8.58	$10.32 per share	4.97
NVO Novo Nordisk A/S	$46.80B	4.00	$4.57 per share	9.16	$6.58 per share	6.37
NVS Novartis	$54.53B	5.23	$10.76 per share	13.89	$22.04 per share	6.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.66	27.53	17.19	1.59	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
GSK GSK	$7.54B	$3.85	13.34	10.02	2.64	17.82%	44.28%	11.49%	7/28/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	9.83	12.18	3.83	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
NVS Novartis	$13.98B	$6.98	21.41	15.23	2.62	24.87%	38.82%	15.16%	7/21/2026 (Estimated)

Latest GSK, NVS, AZN, and NVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/27/2026	Q1 2026	NVS Novartis	$2.11	$1.99	-$0.12	$1.65	$13.44 billion	$13.52 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.36%	+2.30%	65.17%	N/A
GSK GSK	$1.81	3.53%	-7.86%	47.01%	N/A
NVO Novo Nordisk A/S	$1.75	4.18%	+21.74%	41.08%	N/A
NVS Novartis	$3.08	2.06%	+5.28%	44.13%	N/A

Latest GSK, NVS, AZN, and NVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GSK GSK	quarterly	$0.44	3.71%	5/15/2026	5/15/2026	7/9/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.52	0.91	0.71
GSK GSK	0.80	0.79	0.52
NVO Novo Nordisk A/S	0.59	0.79	0.56
NVS Novartis	0.96	0.85	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
GSK GSK	15.74%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
GSK GSK	10.00%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
GSK GSK	66,841	2.03 billion	1.83 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

GSK, AZN, NVS, and NVO Headlines

Recent News About These Companies

Barclays Keeps Their Hold Rating on Novartis AG (NOVN)

2 hours ago | theglobeandmail.com

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

June 8 at 3:00 AM | globenewswire.com

Argus Research Reaffirms Their Buy Rating on Novartis (NVS)

June 6 at 11:33 PM | theglobeandmail.com

Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica

June 5, 2026 | insidermonkey.com

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

June 5, 2026 | zacks.com

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

June 4, 2026 | globenewswire.com

Novartis AG (NYSE:NVS) Given Average Recommendation of "Hold" by Brokerages

June 4, 2026 | americanbankingnews.com

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

June 3, 2026 | globenewswire.com

Novartis announces results on rPFS improvements across subgroups with Pluvicto

June 1, 2026 | finance.yahoo.com

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

June 1, 2026 | globenewswire.com

Experimental Novartis radiopharma drug shows promise in early study

May 31, 2026 | reuters.com

Novartis: H2 Pipeline Readouts Matter, But Valuation Leaves Limited Upside

May 30, 2026 | seekingalpha.com

New Bill: Senator Richard J. Durbin introduces S. 4566: Increasing Access to Lung Cancer Screening Act

May 29, 2026 | quiverquant.comQ

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

May 26, 2026 | globenewswire.com

Novartis (NVS) Positioned for Growth Through Transformative Innovations

May 21, 2026 | finance.yahoo.com

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

May 21, 2026 | globenewswire.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

US Supreme Court rebuffs pharma challenge to Biden-era drug price

May 18, 2026 | reuters.com

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade (NVS)

...

May 18, 2026 | marketbeat.com

Novartis International AG: Novartis tender offer for Advanced Accelerator Applications commences

May 16, 2026 | finanznachrichten.de

Implied Volatility Surging for Novartis Stock Options

May 13, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, AZN, NVS, and NVO Company Descriptions

Astrazeneca NYSE:AZN

$183.36 +1.81 (+1.00%)

Closing price 03:59 PM Eastern

Extended Trading

$183.46 +0.09 (+0.05%)

As of 05:25 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK NYSE:GSK

$51.16 +0.52 (+1.02%)

Closing price 03:59 PM Eastern

Extended Trading

$51.23 +0.07 (+0.14%)

As of 05:42 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Novo Nordisk A/S NYSE:NVO

$42.21 +1.19 (+2.91%)

Closing price 03:59 PM Eastern

Extended Trading

$42.14 -0.07 (-0.16%)

As of 05:51 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$149.18 +2.76 (+1.89%)

Closing price 03:59 PM Eastern

Extended Trading

$148.41 -0.77 (-0.52%)

As of 05:39 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GSK, NVS, AZN, and NVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GSK, NVS, AZN, and NVO Earnings

Compare Dividends

Latest GSK, NVS, AZN, and NVO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GSK, AZN, NVS, and NVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, AZN, NVS, and NVO Company Descriptions

Astrazeneca NYSE:AZN

GSK NYSE:GSK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GSK, NVS, AZN, and NVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GSK, NVS, AZN, and NVO Earnings

Compare Dividends

Latest GSK, NVS, AZN, and NVO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GSK, AZN, NVS, and NVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK, AZN, NVS, and NVO Company Descriptions

Astrazeneca NYSE:AZN

GSK NYSE:GSK

Novo Nordisk A/S NYSE:NVO

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools